Toro Company (The) (NYSE:TTC)
Toro Company (The) (NYSE:TTC), ended its previous trading session at $88.01 showing a loss of -1.16 or -1.3 percent with respect to the price of $89.17 when stock market opened. The company traded 339034 shares over the course of the trading day. Giving the average volume of 491.34 Million over the course of 3 consecutive months. Which signifies a pretty good change over the time with its shares outstanding of 107.71 Million.
Toro Company (The) (NYSE:TTC) is currently trading Higher than its price target which is set to $88 by the analyst. The stock is -2.36% Below its 1-Year High which is $90.14. TTC has a difference of 69.02% from its 1 year low which stands at $52.07. The company is currently rated by analyst who are keeping a close eye on the stock as 2.7. Where 1 means Buy, 2.5 meaning Hold and 5 as Sell.
Toro Company (The) (NYSE:TTC) Performance Snapshot
The stock performed exceptionally bad in the previous week which depicts an decrease of 1.93 percent in the shares price. The company added about 2.78% in its share price over 1-Month. While taking about the performance of the stock over 1-year interval is 13.53 Percent. TTC currently shows 10.47% as its year to date performance.
Toro Company (The) (NYSE:TTC) Price Insight
The stock needs to grow about $-0.0100000000000051 to reach its price target. In order to seek the stock’s directional movements, 20-Days, 50 Days and 200-Days moving averages are 3.74%, 3.91% and 20.11 percent respectively. The stock trades about 1.2 percent of its Float giving its total shares Outstanding are 107.71 Million. TTC gained about 29.62 percent in 6 months showing its Average True Range of 1.8. The company currently has a RSI and Beta of 59.94 and 0.71.
While talking about Toro Company (The) (NYSE:TTC) valuation ratios, the stock trades with a P/S and P/B of 2.85 and 8.99 which is significantly better and attractive as compared to its peers.
Histogenics Corporation (NASDAQ:HSGX)
Performance Indicators of Histogenics Corporation (NASDAQ:HSGX)
Histogenics Corporation (NASDAQ:HSGX) Analytical Review